J&J vaccine meets FDA emergency use standards
Johnson & Johnson's single-dose COVID-19 vaccine candidate met emergency use authorization standards per FDA committee analysis, with 66% efficacy and refrigerated storage. Authorization was pending as of 26 February 2021.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthJ&J vaccine meets FDA emergency use standards
Sign in or subscribeBrowse free archive reportsJohnson & Johnson's single-dose COVID-19 vaccine candidate met emergency use authorization standards per FDA committee analysis, with 66% efficacy and refrigerated storage. Authorization was pending as of 26 February 2021.